Auto saved by Logseq

journals/2024_04_04.md

@@ -68,6 +68,9 @@
 			- Our conclusions and proposal is revisit the dosign strategies for ivm.
 			- Pat Lammie: A couple of questions: great presentation of the data generated. When you where looking at the reductions in egg with T. t. The scatter that you saw with fdc1 or fdc3. What is going in con la gente que no muestra esa reduction?
 			- AK: We have hypothesis: people working in the vet world have shown that having a longer exposure to the drug improve the efficacy. We haven't completed the genomic analysis trying to identify if there is a difference. But the pharmacokinetic analysis shows in Phase II we couldn't identify. We only saw it in blood, not where the parasite is.
+			- PL: The work being done by Sanger is it full genome analysis?
+			- AK: sí. su approach también es ese para este proyecto.
+			-
 			-
 -
 - ## Cosas de gastos del [[Evento]]